BioNTech publishes proof-of-concept data for BNT211 CAR-T cell therapy
Category: #health  | By Mateen Dalal  | Date: 2020-01-04 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

BioNTech publishes proof-of-concept data for BNT211 CAR-T cell therapy

The report will contain data of CAR-T product candidate called BNT211, an autologous CAR-T cell therapy

BioNTech SE, a biotechnology firm based in Germany, recently announced a publication in Science regarding a therapeutic CAR-T approach for solid tumors that uses CAR-T cell amplifying RNA Vaccine, also called CARVac introduced by the company. The report offers preclinical proof-of-concept data for the company’s first CAR-T product candidate called BNT211 which is an autologous CAR-T cell therapy.

It essentially targets oncofetal antigen Claudin 6 (CLDN6) as well as outlines CARVac as an RNA vaccine approach that is widely applicable for the improvement of the efficacy of the CAR-T cell therapies.

Reportedly, CAR-T cell has exhibited considerable clinical efficacy in blood cancers but still tends to face challenges in regards with solid tumors that includes a limited number of identified cancer-specific solid tumors, insufficient persistence of CAR-T cells and inefficient CAR-T cell infiltration into solid tumors.

BioNTech has been aiming to overpower such hurdles by targeting the tumor-specific antigen expressed in several solid tumors, CLDN6, which when combined with an RNA vaccine will promote persistence, efficacy, and amplification of CAR-T cells in vivo.

CAR-T cell therapy combined with CARVac will be underlining the value of cross-platform synergies that would address major challenges for the development of cancer treatment.

Sources confirm that BioNTech has planned to commence Phase 1/2 clinical trial, its first-in-human trial for BNT211, later in the year in solid tumors such as testicular, lung cancer, ovarian and uterine. The manufacturing shall be conducted in-house at the state-of-the-art cell therapy facility BioNTech, which is GMP certified, to support the clinical trials of BNT211. The GMP plant is a certified cell therapy and manufacturing facility located in Idar-Oberstein, Germany, that has been operating since 1999.

BioNTech had initiated a capacity expansion at the facility in the year 2018 and it expects it to be completed by 2020.

 

Source Credit- https://investors.biontech.de/news-releases/news-release-details/biontech-announces-publication-preclinical-data-first-kind-car-t

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Oral-B & iADH partner to make oral care positive & accessible for all

Oral-B & iADH partner to make oral care positive & accessible for all

By Mateen Dalal

Oral-B, a well-known American oral hygiene products brand, has reportedly inked a partnership deal with iADH (International Association of Disability and Oral Health), in order to make oral care more positive, accessible, and inclusive for disabled p...

NEA AND SLA SIGN MOU TO SHARE GLOBAL NAVIGATION SATELLITE SYSTEM (GNSS)-DERIVED MOISTURE DATA FOR WEATHER MONITORING APPLICATION

NEA AND SLA SIGN MOU TO SHARE GLOBAL NAVIGATION SATELLITE SYSTEM (GNSS)-DERIVED MOISTURE DATA FOR WEATHER MONITORING APPLICATION

By Mateen Dalal

Singapore, 2 August 2022 – The National Environment Agency (NEA) and the Singapore Land Authority (SLA) have signed a Memorandum of Understanding (MOU) to develop the use of Global Navigation Satellite System (GNSS) data obtained from SLA&rsqu...

Baidu launches Apollo RT6; seeks expansion of its robotaxi fleet

Baidu launches Apollo RT6; seeks expansion of its robotaxi fleet

By Mateen Dalal

Baidu, a leading China-based artificial intelligence (AI) company and search engine, has reportedly uncovered its most recent electric autonomous driving vehicle. As per credible sources, the new vehicle, Apollo RT6, will be a part of the robotaxi...